Jpmorgan Chase & CO Nautilus Biotechnology, Inc. Transaction History

Jpmorgan Chase & CO

$1.22 Trillion
Q3 2024

A detailed history of Jpmorgan Chase & CO transactions in Nautilus Biotechnology, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 35,603 shares of NAUT stock, worth $84,735. This represents 0.0% of its overall portfolio holdings.

Number of Shares

35,603

Previous 37,617 5.35%

Holding current value

$84,735

Previous $88,000 14.77%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 08, 2024	SELL	$2.24 - $3.08 $4,511 - $6,203	-2,014 Reduced 5.35%	35,603 $101,000
Q2 2024 Aug 12, 2024	SELL	$2.22 - $3.0 $58,572 - $79,152	-26,384 Reduced 41.22%	37,617 $88,000
Q1 2024 May 10, 2024	BUY	$2.41 - $3.18 $8,201 - $10,821	3,403 Added 5.62%	64,001 $188,000
Q4 2023 Feb 12, 2024	BUY	$2.34 - $3.39 $8,920 - $12,922	3,812 Added 6.71%	60,598 $181,000
Q3 2023 Nov 14, 2023	BUY	$2.87 - $3.94 $40,610 - $55,751	14,150 Added 33.19%	56,786 $179,000
Q2 2023 Aug 11, 2023	BUY	$2.21 - $4.52 $6,066 - $12,407	2,745 Added 6.88%	42,636 $165,000
Q1 2023 May 18, 2023	BUY	$1.67 - $2.77 $60,980 - $101,146	36,515 Added 1081.61%	39,891 $110,000
Q1 2023 May 11, 2023	SELL	$1.67 - $2.77 $44,338 - $73,543	-26,550 Reduced 88.72%	3,376 $9,000
Q4 2022 Feb 13, 2023	SELL	$1.55 - $2.47 $5,676 - $9,045	-3,662 Reduced 10.9%	29,926 $54,000
Q3 2022 Nov 14, 2022	BUY	$1.96 - $3.13 $4,547 - $7,261	2,320 Added 7.42%	33,588 $71,000
Q2 2022 Aug 11, 2022	BUY	$2.64 - $4.84 $43,520 - $79,787	16,485 Added 111.51%	31,268 $85,000
Q1 2022 May 11, 2022	BUY	$3.5 - $5.3 $13,429 - $20,336	3,837 Added 35.05%	14,783 $64,000
Q4 2021 Feb 10, 2022	BUY	$4.45 - $6.21 $48,709 - $67,974	10,946 New	10,946 $57,000

Others Institutions Holding NAUT

# of Institutions

Shares Held

64.3M

Call Options Held

1.9K

Put Options Held

100

View Full List

About Nautilus Biotechnology, Inc.

Ticker NAUT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 124,663,000
Market Cap $297M
Description
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company was found...

More about NAUT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Account

Jpmorgan Chase & CO Nautilus Biotechnology, Inc. Transaction History